The utility of Aspirin in Dukes C and High Risk Dukes B Colorectal cancer - The ASCOLT study: Study Protocol for a randomized controlled trial

被引:57
作者
Ali, Raghib [2 ]
Toh, Han-Chong [1 ]
Chia, Whay-Kuang [1 ]
机构
[1] Natl Canc Ctr, Dept Med Oncol, Singapore 169610, Singapore
[2] Univ Oxford, INDOX Canc Res Network, Oxford OX3 7LF, England
基金
英国医学研究理事会;
关键词
ASCOLT; aspirin; platelets; colon; rectal; cancer; inflammation; adjuvant; Dukes B; Dukes C; ADJUVANT TREATMENT; COLON-CANCER; STAGE-III; FLUOROURACIL; LEUCOVORIN; ANGIOGENESIS; LEVAMISOLE; CARCINOMA; THERAPY;
D O I
10.1186/1745-6215-12-261
中图分类号
R-3 [医学研究方法]; R3 [基础医学];
学科分类号
1001 ;
摘要
Background: High quality evidence indicates that aspirin is effective in reducing colorectal polyps; and numerous epidemiological studies point towards an ability to prevent colorectal cancer. However the role of Aspirin as an adjuvant agent in patients with established cancers remains to be defined. Recently a nested case-control study within the Nurses Health cohort suggested that the initiation of Aspirin after the diagnosis of colon cancer reduced overall colorectal cancer specific mortality. Although this data is supportive of Aspirin's biological activity in this disease and possible role in adjuvant therapy, it needs to be confirmed in a randomized prospective trial. Methods/Design: We hypothesize through this randomized, placebo-controlled adjuvant study, that Aspirin in patients with dukes C or high risk dukes B colorectal cancer (ASCOLT) can improve survival in this patient population over placebo control. The primary endpoint of this study is Disease Free Survival and the secondary Endpoint is 5 yr Overall Survival. This study will randomize eligible patients with Dukes C or high risk Dukes B colorectal cancer, after completion of surgery and standard adjuvant chemotherapy (+/- radiation therapy for rectal cancer patients) to 200 mg Aspirin or Placebo for 3 years. Stratification factors include study centre, rectal or colon cancer stage, and type of adjuvant chemotherapy (exposed/not exposed to oxaliplatin). After randomization, patient will be followed up with 3 monthly assessments whilst on study drug and for a total of 5 years. Patients with active peptic ulcer disease, bleeding diathesis or on treatment with aspirin or anti-platelet agents will be excluded from the study. Discussion: This study aims to evaluate Aspirin's role as an adjuvant treatment in colorectal cancer. If indeed found to be beneficial, because aspirin is cheap, accessible and easy to administer, it will positively impact the lives of many individuals in Asia and globally.
引用
收藏
页数:8
相关论文
共 48 条
[1]   Developing innovative models for North-South cooperation in clinical research - experience from the INDOX Cancer Research Network [J].
Ali, R. ;
Raina, V. .
ANNALS OF ONCOLOGY, 2008, 19 (05) :831-833
[2]   Phase III Trial Assessing Bevacizumab in Stages II and III Carcinoma of the Colon: Results of NSABP Protocol C-08 [J].
Allegra, Carmen J. ;
Yothers, Greg ;
O'Connell, Michael J. ;
Sharif, Saima ;
Petrelli, Nicholas J. ;
Colangelo, Linda H. ;
Atkins, James N. ;
Seay, Thomas E. ;
Fehrenbacher, Louis ;
Goldberg, Richard M. ;
O'Reilly, Seamus ;
Chu, Luis ;
Azar, Catherine A. ;
Lopa, Samia ;
Wolmark, Norman .
JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (01) :11-16
[3]   Oxaliplatin, fluorouracil, and leucovorin as adjuvant treatment for colon cancer [J].
Andre, T ;
Boni, C ;
Mounedji-Boudiaf, L ;
Navarro, M ;
Tabernero, J ;
Hickish, T ;
Topham, C ;
Zaninelli, M ;
Clingan, P ;
Bridgewater, J ;
Tabah-Fisch, I ;
de Gramont, A .
NEW ENGLAND JOURNAL OF MEDICINE, 2004, 350 (23) :2343-2351
[4]  
[Anonymous], CELECOXIB COMBINED F
[5]  
[Anonymous], SING CANC REG INT RE
[6]  
[Anonymous], J CLIN ONCOL
[7]   A randomized trial of aspirin to prevent colorectal adenomas [J].
Baron, JA ;
Cole, BF ;
Sandler, RS ;
Haile, RW ;
Ahnen, D ;
Bresalier, R ;
McKeown-Eyssen, G ;
Summers, RW ;
Rothstein, R ;
Burke, CA ;
Snover, DC ;
Church, TR ;
Allen, JI ;
Beach, M ;
Beck, GJ ;
Bond, JH ;
Byers, T ;
Greenberg, ER ;
Mandel, JS ;
Marcon, N ;
Mott, LA ;
Pearson, L ;
Saibil, F ;
van Stolk, RU .
NEW ENGLAND JOURNAL OF MEDICINE, 2003, 348 (10) :891-899
[8]   Tumorigenesis and the angiogenic switch [J].
Bergers, G ;
Benjamin, LE .
NATURE REVIEWS CANCER, 2003, 3 (06) :401-410
[9]  
Boyle P, 2008, WHO 2008 WORLD CANC
[10]   Prospective study of urinary prostaglandin E2 metabolite and colorectal cancer risk [J].
Cai, Qiuyin ;
Gao, Yu-Tang ;
Chow, Wong-Ho ;
Shu, Xiao-Ou ;
Yang, Gong ;
Ji, Bu-Tian ;
Wen, Wanqing ;
Rothman, Nathaniel ;
Li, Hong-Lan ;
Morrow, Jason D. ;
Zheng, Wei .
JOURNAL OF CLINICAL ONCOLOGY, 2006, 24 (31) :5010-5016